CoChat

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

Open access
Fang, Douglas D., Zhang, Cathy C., Gu, Yin, Jani, Jitesh P., Cao, Joan, Tsaparikos, Konstantinos, Yuan, Jing, Thiel, Melissa, Jackson-Fisher, Amy, Zong, Qing, Lappin, Patrick B., Hayashi, Tomoko, Schwab, Richard B., Wong, Anthony, John-Baptiste, Annette, Bagrodia, Shubha, Los, Geritt, Bender, Steve, Christensen, James, VanArsdale, Todd · 2013 · PLoS ONE
Cited by 44

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settings. In light of the recent discovery of tumor-initiating cancer stem cells (CSCs) in various tumor types, we developed an in vitro CSC model from xenograft tumors established in mice from a colorectal cancer patient tumor in which the CD133+/EpCAM+ population represented tumor-initiating cells. CD133+/EpCAM+ CSCs were enriched under stem cell culture conditions and formed 3-dimensional tumor spheroids. Tumor spheroid cells exhibited CSC properties, including the capability for differentiation and self-renewal, higher tumorigenic potential and chemo-resistance. Genetic analysis using an OncoCarta™ panel revealed a PIK3CA (H1047R) mutation in these cells. Using a dual PI3K/mTOR inhibitor, PF-04691502, we then showed that blockage of the PI3K/mTOR pathway inhibited the in vitro proliferation of CSCs and in vivo xenograft tumor growth with manageable toxicity. Tumor growth inhibition in mice was accompanied by a significant reduction of phosphorylated Akt (pAKT) (S473), a well-established surrogate biomarker of PI3K/mTOR signaling pathway inhibition. Collectively, our data suggest that PF-04691502 exhibits potent anticancer activity in colorectal cancer by targeting both PIK3CA (H1047R) mutant CSCs and their derivatives. These results may assist in the clinical development of PF-04691502 for the treatment of a subpopulation of colorectal cancer patients with poor outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0067258

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 44

Metadata

Authors
Fang, D. D., Zhang, C. C., Gu, Y., Jani, J. P., Cao, J., Tsaparikos, K., Yuan, J., Thiel, M., Jackson-Fisher, A., Zong, Q., Lappin, P. B., Hayashi, T., Schwab, R. B., Wong, A., John-Baptiste, A., Bagrodia, S., Los, G., Bender, S., Christensen, J., & VanArsdale, T.
Venue
PLoS ONE
Published
2013-06-27
Volume
8
Issue
6
Pages
e67258
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2032204557
Cited by
44
References
5
FWCI
2.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. https://app.cochat.ai/papers/10.1371/journal.pone.0067258
The paper
Fang, D. D., Zhang, C. C., Gu, Y., Jani, J. P., Cao, J., Tsaparikos, K., Yuan, J., Thiel, M., Jackson-Fisher, A., Zong, Q., Lappin, P. B., Hayashi, T., Schwab, R. B., Wong, A., John-Baptiste, A., Bagrodia, S., Los, G., Bender, S., Christensen, J., & VanArsdale, T. (2013). Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS ONE. https://doi.org/10.1371/journal.pone.0067258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.